Drug Trial Radar · NCT02612454
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
880
Actual
Start
Oct 15, 2015
Primary completion
Oct 9, 2026
Study completion Oct 9, 2026
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Nov 23, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD. The secondary objectives of the study are: * To assess the long-term efficacy of dupilumab in pediatric participants with AD * To assess the trough concentrations of functional dupilumab in serum and the immunogenicity in pediatric participants with AD after re-treatment with dupilumab Optional Pre-filled Pen (PFP) Sub-Study in pediatric patients ≥2 to \<12 years of age with AD Co-Primary Objectives are: * To evaluate the pharmacokinetic (PK) of dupilumab PFPs * To evaluate the safety of dupilumab PFPs Secondary Objective is: \- To evaluate the immunogenicity of dupilumab PFPs
Conditions
- Atopic Dermatitis
Interventions
DupilumabDrug
Weight-tiered dosing administered subcutaneous (SC)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of treatment-emergent adverse events (TEAEs) per participant year from baseline through the last study visitTime frame: Baseline up to week 272
- Number of participants with at least one TEAE per participant year from baseline through the last study visitTime frame: Baseline up to week 272
- OPTIONAL SUB-STUDY: Pharmacokinetic (PK) of dupilumab: Peak concentration (Cmax)Time frame: Up to week 16
- OPTIONAL SUB-STUDY: PK of dupilumab: Trough concentration (Ctrough)Time frame: Up to week 16
- OPTIONAL SUB-STUDY: Incidence of TEAEs during the 12-week PFP treatment period and during entire sub-studyTime frame: Up to week 16
- OPTIONAL SUB-STUDY: Incidence of SAEs during the 12-week PFP treatment period and during entire sub-studyTime frame: Up to week 16
Locations
84 sites in 7 countries. Site status is shown where the registry gives one.
Regeneron Investigational Site
Birmingham, Alabama
Regeneron Investigational Site
Gilbert, Arizona
Regeneron Investigational Site
Bakersfield, California
Regeneron Investigational Site
Long Beach, California
Regeneron Investigational Site
Los Angeles, California
Regeneron Investigational site
Mission Viejo, California
Regeneron Investigational Site
Orange, California
Regeneron Investigational Site
Palo Alto, California
Regeneron Investigational Site
Rolling Hills Estates, California
Regeneron Investigational Site
San Diego, California
Regeneron Investigational Site
Centennial, Colorado
Regeneron Investigational Site
Washington D.C., District of Columbia
Regeneron Investigational Site
Coral Gables, Florida
Regeneron Investigational Site
Tampa, Florida
Regeneron Investigational Site
Tampa, Florida
Regeneron Investigational Site
Columbus, Georgia
Regeneron Investigational Site
Macon, Georgia
Regeneron Investigational Site
Sandy Springs, Georgia
Regeneron Investigational Site
Chicago, Illinois
Regeneron Investigational Site
Skokie, Illinois
Regeneron Investigational site
Plainfield, Indiana
Regeneron Investigational Site
Rockville, Maryland
Regeneron Investigational Site
Boston, Massachusetts
Regeneron Investigational Site
Boston, Massachusetts
Regeneron Investigational Site
Ypsilanti, Michigan
Regeneron Investigational Site
Plymouth, Minnesota
Regeneron Investigational Site
St Louis, Missouri
Regeneron Investigational Site
Forest Hills, New York
Regeneron Investigational Site
New York, New York
Regeneron Investigational Site
Rochester, New York
Regeneron Investigational Site
Gahanna, Ohio
Regeneron Investigational Site
Portland, Oregon
Regeneron Investigational site
Philadelphia, Pennsylvania
Regeneron Investigational Site
Charleston, South Carolina
Regeneron Investigational Site
North Charleston, South Carolina
Regeneron Investigational Site
Bellaire, Texas
Regeneron Investigational Site
Fort Worth, Texas
Regeneron Investigational Site
San Antonio, Texas
Regeneron Investigational Site
Norfolk, Virginia
Regeneron Investigational Site
Seattle, Washington
Showing 40 of 84 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.